These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 36114704

  • 1. Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial.
    Tanaka A, Imai T, Shimabukuro M, Nakamura I, Matsunaga K, Ozaki Y, Minamino T, Sata M, Node K, CANDLE trial investigators.
    J Diabetes Investig; 2022 Dec; 13(12):1990-1999. PubMed ID: 36114704
    [Abstract] [Full Text] [Related]

  • 2. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
    Tanaka A, Toyoda S, Imai T, Shiina K, Tomiyama H, Matsuzawa Y, Okumura T, Kanzaki Y, Onishi K, Kiyosue A, Nishino M, Sakata Y, Node K, CANDLE trial investigators.
    Cardiovasc Diabetol; 2021 Sep 03; 20(1):175. PubMed ID: 34479543
    [Abstract] [Full Text] [Related]

  • 3. Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.
    Kusunose K, Imai T, Tanaka A, Dohi K, Shiina K, Yamada T, Kida K, Eguchi K, Teragawa H, Takeishi Y, Ohte N, Yamada H, Sata M, Node K, CANDLE Trial Investigators.
    Cardiovasc Diabetol; 2021 Sep 14; 20(1):186. PubMed ID: 34521417
    [Abstract] [Full Text] [Related]

  • 4. Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial.
    Tanaka A, Imai T, Shimabukuro M, Taguchi I, Sezai A, Toyoda S, Watada H, Ako J, Node K, CANDLE trial investigators.
    Cardiovasc Diabetol; 2022 Aug 08; 21(1):151. PubMed ID: 35941584
    [Abstract] [Full Text] [Related]

  • 5. Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
    Tanaka A, Inoue T, Kitakaze M, Oyama J, Sata M, Taguchi I, Shimizu W, Watada H, Tomiyama H, Ako J, Sakata Y, Anzai T, Uematsu M, Suzuki M, Eguchi K, Yamashina A, Saito Y, Sato Y, Ueda S, Murohara T, Node K.
    Cardiovasc Diabetol; 2016 Apr 04; 15():57. PubMed ID: 27044332
    [Abstract] [Full Text] [Related]

  • 6. Body fluid regulation via chronic inhibition of sodium-glucose cotransporter-2 in patients with heart failure: a post hoc analysis of the CANDLE trial.
    Fujiki S, Tanaka A, Imai T, Shimabukuro M, Uehara H, Nakamura I, Matsunaga K, Suzuki M, Kashimura T, Minamino T, Inomata T, Node K, CANDLE Trial Investigators.
    Clin Res Cardiol; 2023 Jan 04; 112(1):87-97. PubMed ID: 35729430
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes.
    Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K.
    Cardiovasc Diabetol; 2018 May 22; 17(1):73. PubMed ID: 29788955
    [Abstract] [Full Text] [Related]

  • 14. Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.
    Figtree GA, Rådholm K, Barrett TD, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Matthews DR, Shaw W, Neal B.
    Circulation; 2019 May 28; 139(22):2591-2593. PubMed ID: 30882240
    [No Abstract] [Full Text] [Related]

  • 15. Canagliflozin for Japanese patients with chronic heart failure and type II diabetes.
    Sezai A, Sekino H, Unosawa S, Taoka M, Osaka S, Tanaka M.
    Cardiovasc Diabetol; 2019 Jun 05; 18(1):76. PubMed ID: 31167663
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus.
    Ejiri K, Miyoshi T, Kihara H, Hata Y, Nagano T, Takaishi A, Toda H, Nanba S, Nakamura Y, Akagi S, Sakuragi S, Minagawa T, Kawai Y, Nishii N, Fuke S, Yoshikawa M, Nakamura K, Ito H, MUSCAT‐HF Study Investigators †.
    J Am Heart Assoc; 2020 Aug 18; 9(16):e015103. PubMed ID: 32805185
    [Abstract] [Full Text] [Related]

  • 18. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, Berry C, Chong V, Coyle L, Docherty KF, Dreisbach JG, Labinjoh C, Lang NN, Lennie V, McConnachie A, Murphy CL, Petrie CJ, Petrie JR, Speirits IA, Sourbron S, Welsh P, Woodward R, Radjenovic A, Mark PB, McMurray JJV, Jhund PS, Petrie MC, Sattar N.
    Circulation; 2021 Feb 09; 143(6):516-525. PubMed ID: 33186500
    [Abstract] [Full Text] [Related]

  • 19. Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with type 2 diabetes mellitus: The SHIFT-J study.
    Kario K, Hoshide S, Okawara Y, Tomitani N, Yamauchi K, Ohbayashi H, Itabashi N, Matsumoto Y, Kanegae H.
    J Clin Hypertens (Greenwich); 2018 Oct 09; 20(10):1527-1535. PubMed ID: 30246286
    [Abstract] [Full Text] [Related]

  • 20. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
    Agarwal R, Anker SD, Filippatos G, Pitt B, Rossing P, Ruilope LM, Boletis J, Toto R, Umpierrez GE, Wanner C, Wada T, Scott C, Joseph A, Ogbaa I, Roberts L, Scheerer MF, Bakris GL.
    Nephrol Dial Transplant; 2022 Jun 23; 37(7):1261-1269. PubMed ID: 34850173
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.